Leap Therapeutics (FRA:5MC) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Leap Therapeutics's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Leap Therapeutics's average Accounts Receivable for the three months ended in Dec. 2024 was €0.00 Mil.

Leap Therapeutics Receivables Turnover Historical Data

The historical data trend for Leap Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Receivables Turnover Chart

Leap Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

Leap Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Leap Therapeutics's Receivables Turnover

For the Biotechnology subindustry, Leap Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Leap Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Leap Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Leap Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Leap Therapeutics's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Leap Therapeutics (FRA:5MC) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Leap Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

LPTX:USA 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Headlines

No Headlines